



Medical Microbiology

The prevalence of aminoglycoside-modifying enzyme and virulence genes among enterococci with high-level aminoglycoside resistance in Inner Mongolia, China



Haiying Niu^a, Hui Yu^b, Tangping Hu^a, Gailin Tian^a, Lixia Zhang^a, Xiang Guo^a, Hai Hu^{c,*}, Zhanli Wang^{a,*}

^a The First Affiliated Hospital, Baotou Medical College, Baotou, China

^b The Second Affiliated Hospital, Baotou Medical College, Baotou, China

^c Department of Pathophysiology, Baotou Medical College, Baotou, China

ARTICLE INFO

Article history:

Received 12 January 2015

Accepted 22 December 2015

Available online 20 April 2016

Associate Editor: Ana Lúcia da Costa Darini

Keywords:

Enterococcus

High-level aminoglycoside resistance

Aminoglycoside-modifying enzyme gene

Virulence determinant

ABSTRACT

This study highlights the prevalence of aminoglycoside-modifying enzyme genes and virulence determinants among clinical enterococci with high-level aminoglycoside resistance in Inner Mongolia, China. Screening for high-level aminoglycoside resistance against 117 enterococcal clinical isolates was performed using the agar-screening method. Out of the 117 enterococcal isolates, 46 were selected for further detection and determination of the distribution of aminoglycoside-modifying enzyme-encoding genes and virulence determinants using polymerase chain reaction -based methods. *Enterococcus faecium* and *Enterococcus faecalis* were identified as the species of greatest clinical importance. The *aac(6')-Ie-aph(2'')-Ia* and *ant(6')-Ia* genes were found to be the most common aminoglycoside-modifying enzyme genes among high-level gentamicin resistance and high-level streptomycin resistance isolates, respectively. Moreover, *gelE* was the most common virulence gene among high-level aminoglycoside resistance isolates. Compared to *Enterococcus faecium*, *Enterococcus faecalis* harbored multiple virulence determinants. The results further indicated no correlation between aminoglycoside-modifying enzyme gene profiles and the distribution of virulence genes among the enterococcal isolates with high-level gentamicin resistance or high-level streptomycin resistance evaluated in our study.

© 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding authors.

E-mails: btyxyhh@163.com (H. Hu), wang.zhanli@hotmail.com (Z. Wang).

<http://dx.doi.org/10.1016/j.bjm.2016.04.003>

1517-8382/© 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Enterococci have emerged as an important source of hospital-acquired infections, including those related to the surgical site, respiratory tract, urinary tract, skin and soft tissue, and bacteremia.¹ Several studies have indicated increasing enterococci resistance to a broad range of antimicrobial agents via intrinsic and acquired mechanisms.² High-level aminoglycoside resistance (HLAR) has been recognized for several decades. Gentamicin and streptomycin are the two main aminoglycosides used in clinical practice. Recently, high-level gentamicin resistance (HLGR) (MIC $\geq 500 \mu\text{g/ml}$) and high-level streptomycin resistance (HLSR) (MIC $\geq 2000 \mu\text{g/ml}$) have been reported worldwide.^{3–8} Clinical experience supports the use of aminoglycosides along with cell-wall inhibitors for treating serious enterococcal infections.⁹ However, high-level resistance of clinical isolates of *Enterococcus* species to aminoglycosides negates the synergism between cell-wall inhibitors and aminoglycosides, making the treatment of serious enterococcal infections difficult.¹⁰

In general, enterococci are intrinsically resistant to clinically achievable concentrations of aminoglycosides. However, high-level resistance to aminoglycosides is primarily due to acquisition of genes encoding aminoglycoside-modifying enzymes (AMEs).¹¹ Over past decades, a great deal of research has been devoted to understanding the mechanisms behind the high-level resistance of enterococci to aminoglycosides. Until now, the following three classes of AMEs have been identified: acetyltransferase (AAC), aminoglycoside phosphotransferase (APH), and aminoglycoside nucleotidyltransferase (ANT).¹² The high-level resistance of enterococci to gentamicin is predominantly mediated by *aac(6')-Ie-aph(2'')-Ia*, which encodes the bifunctional AME, AAC(6')-APH(2'').¹³ Ten years ago, *aph(2'')-Ib*, *aph(2'')-Ic*, and *aph(2'')-Id* were detected as newer AME genes conferring HLGR among enterococci.^{14–16} Furthermore, HLSR among enterococci is mediated by *aph(3')-IIIa* and *ant(6')-Ia* encoding for APH(3') and ANT(6')-Ia, respectively.^{3,11}

Additionally, the rise of drug-resistant virulent strains of enterococci is a serious problem in the treatment and control of enterococcal infections. The pathogenicity of enterococci is due to the presence of virulence determinants, such as the *Enterococcus faecalis* (*E. faecalis*) antigen A (*efaA*), adhesion of collagen from *E. faecalis* (*ace*) and products involved in aggregation (*agg*), biosynthesis of an extracellular metalloendopeptidase (*gelE*), biosynthesis of cytolysin (*cylA*) and immune evasion (*esp*).¹⁷ Previous research has shown that clinical isolates of the *Enterococcus* species possess distinctive patterns of virulence factors.¹⁸

The difficulty in treating enterococcal infections is associated with determinants of virulence and antimicrobial resistance. Therefore, accurate identification of antibiotic susceptibility patterns and virulence determinants is essential for choosing appropriate therapies and means of infection control. The goal of the present study was to investigate the occurrence of HLAR among enterococci in Inner Mongolia, China. Additionally, the prevalence of six AME encoding genes, *aac(6')-Ie-aph(2'')-Ia*, *aph(2'')-Ib*, *aph(2'')-Ic*, *aph(2'')-Id*, *aph(3')-IIIa* and *ant(6')-Ia*, among enterococcal

isolates collected from different specimen sources were investigated. Moreover, the presence of virulence determinants, such as *efaA*, *ace*, *agg*, *gelE*, *cylA* and *esp*, was detected.

Experimental

Bacterial strains and identification

A total of 117 clinical isolates of enterococci were collected from four hospitals in Inner Mongolia, China, between May 2012 and May 2014. Duplicate isolates were excluded from the study. Institutional ethical clearance was obtained. The isolates were identified as enterococci by conventional biochemical tests and VITEK 2 Compact (BioMérieux, France). Identifications of *E. faecalis*, *E. faecium* and the other strains were further confirmed via PCR analysis using *ddl_{E. faecium}*, *ddl_{E. faecalis}* and 16S rDNA genes, respectively.¹⁹ The isolates were then stored at -80°C . Table 1 shows the primers and the product sizes of all the genes analyzed.^{19–23}

Detection of HLAR in enterococci

Screening for HLAR was performed using the agar-screening method according to the standards and interpretive criteria described by the Clinical and Laboratory Standards Institute (CLSI).²⁴ Briefly, brain heart infusion agar containing gentamicin ($500 \mu\text{g/ml}$) and streptomycin ($2000 \mu\text{g/ml}$) was used. Plates were incubated for 24 h at 37°C . The aminoglycoside-susceptible strain *E. faecalis* ATCC 29212 and the aminoglycoside-resistant strain *E. faecalis* ATCC 51299 were utilized as controls for HLAR detection.

Amplification of AMEs and virulence genes

The total DNA template was extracted from enterococci according to the instruction manuals of commercial DNA extraction kits (Hangzhou BioSci Biotech Co., Ltd, China). A PCR method was used to detect the presence of AME and virulence genes.^{20–23} The primer couples, product sizes of the genes and annealing temperatures are shown in Table 1. PCR amplification was performed using $1 \mu\text{g}$ of the template DNA, $1 \mu\text{l}$ of each primer (100 pmol), and $25 \mu\text{l}$ of $2\times$ PCR master mix (Hangzhou BioSci Biotech Co., Ltd, China) in a total volume of $50 \mu\text{l}$. A C1000 Touch thermocycler (Bio-Rad, USA) was also employed. PCR conditions were as follows: initial denaturation at 94°C for 3 min; 35 cycles of denaturation at 94°C for 30 s, annealing for 30 s and elongation at 72°C for 1 min, and final extension at 72°C for 5 min. PCR products were analyzed by electrophoresis on 1% agarose gel following staining with ethidium bromide.

Statistical analysis

All statistical analyses were performed using Statistical Package for Social Sciences (SPSS) software (version 11.5). A *p* value < 0.05 was considered statistically significant.

Table 1 – PCR protocols used in this study.

Gene	Primers (5'–3')	Size (bp)	Annealing temperature (°C)	Reference
<i>ddl_{E. faecium}</i>	F-TTGAGGCAGACCAGATTGACG R-TATGACAGCGACTCCGATTCC	658	54	Macovei and Zurek ¹⁹
<i>ddl_{E. faecalis}</i>	F-TCAAGTACAGTTAGTCTTTATTAG R-ACGATTCAAAGCTAACTGAATCAGT	941	54	Macovei et al. ¹⁹
16S rDNA	F-GGATTAGATACCCTGGTAGTCC R-TCGTTGCGGGACTTAACCCAAC	320	54	Macovei et al. ¹⁹
<i>aac(6')-Ie-aph(2'')-Ia</i>	F-CAGGAATTTCGAAAATGGTAGAAAAG R-CACAATCGACTAAAGAGTACCAATC	369	56	Emaneini et al. ²³
<i>aph(2'')-Ib</i>	F-CTTGGACGCTGAGATATATGAGCAC R-GTTGTAGCAATTCAGAAACACCCCTT	867	56	Emaneini et al. ²³
<i>aph(2'')-Ic</i>	F-CCACAATGATAATGACTCAGTTCCC R-CCACAGCTTCCGATAGCAAGAG	444	56	Emaneini et al. ²³
<i>aph(2'')-Id</i>	F-GTGGTTTTTACAGGAATGCCATC R-CCCTCTTCATACCAATCCATATAACC	641	56	Emaneini et al. ²³
<i>aph(3')-IIIa</i>	F-GGCTAAAATGAGAATATCACCGG R-CTTTAAAAAATCATACAGCTCGCG	523	56	Emaneini et al. ²³
<i>ant(6')-Ia</i>	F-ACTGGCTTAATCAATTTGGG R-GCCTTTCCGCCACCTCACCG	577	56	Sepúlveda et al. ²²
<i>cylA</i>	F-TGGATGATAGTGATAGGAAGT R-TCTACAGTAAATCTTTCGTCA	517	54	Reviriego et al. ²¹
<i>gelE</i>	F-AGTTCATGTCTATTTTCTTCAC R-CTTCATTATTTACACGTTTG	402	56	Duprè et al. ²⁰
<i>esp</i>	F-TTACCAAGATGGTTCTGTAGGCAC R-CCAAGTATACTTAGCATCTTTTGG	936	56	Duprè et al. ²⁰
<i>ace</i>	F-AAAGTAGAATTAGATCCACAC R-TCTATCACATTCGGTTGCG	320	56	Duprè et al. ²⁰
<i>agg</i>	F-CCAGTAATCAGTCCAGAAACAACC R-TAGCTTTTTTTCATTCTTGTTGTTGTT	406	53	Duprè et al. ²⁰
<i>efaA</i>	F-CGTGAGAAAGAAATGGAGGA R-CTACTAACACGTCACGAATG	499	56	Duprè et al. ²⁰

Results and discussion

Results

Identification of *Enterococcus* species

A total of 117 strains of enterococci were isolated from various clinical samples, including urine 48/117 (41.0%), wounds 28/117 (23.9%), bile 18/117 (15.4%), vaginal/semen swabs 6/117 (5.1%), pus 6/117 (5.1%), blood 3/117 (2.6%), sputum 2/117 (1.7%), and others 6/117 (5.1%). The predominant species observed in our study were *E. faecium* 63/117 (53.8%) and *E. faecalis* 33/117 (28.2%). We also detected *E. avium* 11/117 (9.4%), *E. gallinarum* 6/117 (5.1%), *E. casseliflavus* 3/117 (2.6%), and *E. durans* 1/117 (0.9%).

Detection of HLAR in enterococci

Resistance rates were determined using the agar-screening method. Among the 117 isolates tested, 50/117 (42.7%) were HLGR, and 32/117 (27.4%) were HLSR. A total of 12/117 (10.3%) of our study isolates were both HLGR and HLSR. The highest resistance was observed among *E. faecium*, followed by *E. faecalis* and *E. avium*.

PCR amplification of AME genes in gentamicin-resistant or streptomycin-resistant isolates

Of the 117 enterococcal isolates evaluated, 46 were selected for further detection and determination of distributions of AME encoding genes (Table 2). Of 28 HLGR isolates (Table 2),

25 (89.3%) carried *aac(6')-Ie-aph(2'')-Ia*, 2 (7.1%) carried *aph(2'')-Ic*, 3 (10.7%) carried *aph(2'')-Id*, and 7 (25.0%) carried *aph(3')-IIIa*. However, *aph(2'')-Ib* was not detected among the isolates evaluated in this study. Some HLGR isolates carried multiple AME genes. Two isolates (7.1%) carried *aac(6')-Ie-aph(2'')-Ia* and *aph(2'')-Ic*; 3 isolates (10.7%) carried *aac(6')-Ie-aph(2'')-Ia* and *aph(2'')-Id*; and 6 isolates (21.4%) carried *aac(6')-Ie-aph(2'')-Ia* and *aph(3')-IIIa*.

Similarly, of the 14 HLSR isolates identified in our study (Table 3), 10 (71.4%) carried *ant(6')-Ia*; 8 (57.1%) carried *aph(3')-IIIa*; and 7 (50.0%) carried both *ant(6')-Ia* and *aph(3')-IIIa*. PCR analysis revealed the absence of resistance genes in susceptible isolates.

PCR amplification of AME genes in both gentamicin- and streptomycin-resistant isolates

Table 4 shows the AME gene profiles of both HLGR and HLSR isolates. Of the 12 isolates analyzed, all 12 (100%) carried *aac(6')-Ie-aph(2'')-Ia*; 9 (75.0%) carried *ant(6')-Ia*; 7 (58.3%) carried *aph(3')-IIIa*; 2 (16.7%) carried *aph(2'')-Id*; and 1 (8.3%) carried *aph(2'')-Ic*. Moreover, 11 isolates (91.7%) carried multiple (two to four) AME genes. Five isolates (41.7%) carried two genes; 4 isolates (33.3%) carried three genes; and 2 isolates (16.7%) carried four genes.

PCR amplification of virulence genes in enterococci

Table 5 shows the presence of virulence genes among HLAR isolates. Of the 30 isolates evaluated, 10 (33.3%) carried *gelE*; 8 (26.7%) carried *efaA*; 7 (23.3%) carried *esp*; 7 (23.3%) carried *cylA*;

Table 2 – Distributions of aminoglycoside modifying enzyme-encoding genes in enterococci with high-level gentamicin resistance. Some isolates carried multiple aminoglycoside modifying enzyme-encoding genes.

AME gene	Distribution of high-level gentamicin resistance in enterococci (n = 28)			Total no. (%) of isolates
	<i>E. faecium</i> (n = 19)	<i>E. faecalis</i> (n = 7)	<i>E. avium</i> (n = 2)	
<i>aac</i> (6')-Ie-aph(2'')-Ia	18	5	2	25 (89.3%)
<i>aph</i> (2'')-Ib	–	–	–	–
<i>aph</i> (2'')-Ic	–	2	–	2 (7.1%)
<i>aph</i> (2'')-Id	2	–	1	3 (10.7%)
<i>aph</i> (3')-IIIa	6	1	–	7 (25.0%)
<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>aph</i> (2'')-Ic	–	2	–	2 (7.1%)
<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>aph</i> (2'')-Id	2	–	1	3 (10.7%)
<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>aph</i> (3')-IIIa	6	–	–	6 (21.4%)

Table 3 – Distributions of aminoglycoside modifying enzyme-encoding genes in enterococci with high-level streptomycin resistance. Some isolates carried multiple aminoglycoside modifying enzyme-encoding genes.

AME gene	Distribution of high-level streptomycin resistance in enterococci (n = 14)		Total no. (%) of isolates
	<i>E. faecium</i> (n = 12)	<i>E. faecalis</i> (n = 2)	
<i>ant</i> (6')-Ia	9	1	10 (71.4%)
<i>aph</i> (3')-IIIa	7	1	8 (57.1%)
<i>ant</i> (6')-Ia + <i>aph</i> (3')-IIIa	6	1	7 (50.0%)

Table 4 – Distributions of aminoglycoside modifying enzyme-encoding genes in enterococci with high-level resistance to both streptomycin and gentamicin.

Enterococcal species	Strain	AME gene profile
<i>E. faecium</i>	6	<i>aac</i> (6')-Ie-aph(2'')-Ia
	13	<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>ant</i> (6')-Ia
	15	<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>aph</i> (2'')-Id
	20	<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>ant</i> (6')-Ia
	21	<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>aph</i> (3')-IIIa + <i>ant</i> (6')-Ia
	29	<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>ant</i> (6')-Ia
	30	<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>aph</i> (3')-IIIa + <i>ant</i> (6')-Ia
	34	<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>aph</i> (3')-IIIa + <i>ant</i> (6')-Ia
	43	<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>aph</i> (3')-IIIa
	49	<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>aph</i> (3')-IIIa + <i>ant</i> (6')-Ia
	51	<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>aph</i> (2'')-Id + <i>aph</i> (3')-IIIa + <i>ant</i> (6')-Ia
<i>E. faecalis</i>	44	<i>aac</i> (6')-Ie-aph(2'')-Ia + <i>aph</i> (2'')-Ic + <i>aph</i> (3')-IIIa + <i>ant</i> (6')-Ia

Table 5 – Distributions of virulence genes in enterococci with high-level aminoglycoside resistance.

Virulence gene	Distribution of high-level aminoglycoside resistance in enterococci (n = 30)			Total no. (%) of isolates
	<i>E. faecium</i> (n = 20)	<i>E. faecalis</i> (n = 8)	<i>E. avium</i> (n = 2)	
<i>gelE</i>	4	6	0	10 (33.3%)
<i>esp</i>	2	4	1	7 (23.3%)
<i>cylA</i>	3	4	0	7 (23.3%)
<i>ace</i>	0	1	0	1 (3.3%)
<i>agg</i>	0	0	0	0 (0%)
<i>efaA</i>	0	8	0	8 (26.7%)

and 1 (3.3%) carried *ace*. The *agg* gene was not detected in any of isolates. Moreover, AME gene profiles and distributions of virulence determinants were compared among HLGR or HLSR isolates, and no significant correlations were found.

Discussion

Enterococci have long been considered one of the most common sources of nosocomial pathogens. The rise of drug-resistant virulent strains of enterococci presents a serious

problem with regard to controlling enterococcal infections. Aminoglycoside antibiotics provide efficient therapies for severe enterococcal infections. However, the introduction of two aminoglycoside antibiotics (gentamicin and streptomycin) was followed by the emergence of resistance in enterococci.

To date, several *Enterococcus* species have been reported, including *E. faecium*, *E. faecalis*, *E. avium*, *E. durans*, *E. gallinarum*, *E. casseliflavus*, *E. raffinosus*, *E. mundtii*, *E. malodoratus*, and *E. hirae*.²⁵ Similar to previous findings in China,²⁶

E. faecium and *E. faecalis* comprise the predominant conditionally pathogenic bacteria in the present report. Additionally, our antibiotic susceptibility test results identified 42.7% HLGR and 27.4% HLSR clinical isolates, similar to other reports.⁹ Moreover, in agreement with previous studies,⁹ HLGR was found to be more common than HLSR in enterococci species.

HLAR is primarily due to the presence of AME genes. HLGR has reportedly been associated with *aac(6')-Ie-aph(2'')-Ia*, *aph(2'')-Ib*, *aph(2'')-Ic*, *aph(2'')-Id*, and *aph(3')-IIIa*. However, HLSR is mainly mediated by *aph(3')-IIIa* and *ant(6')-Ia*.^{3,27} To understand HLAR in enterococci in our region, we investigated the distribution of AME genes among enterococci. As reported in other studies,^{22,27} our analyses identified *aac(6')-Ie-aph(2'')-Ia* and *ant(6')-Ia* as the most common AME genes among HLGR and HLSR isolates, respectively. It is noteworthy that some HLAR isolates did not harbor any AME genes. We presume that this phenomenon may be due to the action of other resistance mechanisms. On the other hand, we detected some isolates that co-harbored two, three, or four AME genes simultaneously, consistent with previous studies.²⁸

The distributions of virulence genes among enterococci were further investigated. As reported in other studies,²⁹ *gelE* was identified as the most frequent virulence factor and was more common in *E. faecalis* than *E. faecium*. *Esp*, *cylA* and *ace* genes were found in 23.3%, 23.3% and 3.3% of the HLAR isolates, respectively. Recently, Sharifi et al. reported that 52.1% of enterococci from hospitalized patients with urinary tract infections tested positive for the *esp* gene,³⁰ this value is higher than that determined by the present study. Like previous reports, our findings found that all HLAR *E. faecalis* isolates harbored *efaA*.³¹ However, *agg* was not detected in any of the enterococci isolates studied herein. Similar to previous studies,³² *E. faecium* and *E. faecalis* strains showed significantly different patterns with regard to the incidence of virulence determinants. Contrary to *E. faecium*, *E. faecalis* harbored multiple virulence genes.

Conclusions

This study indicates that enterococci recovered from clinical samples in Inner Mongolia, China, contain a variety of AME genes and virulence determinants. The *aac(6')-Ie-aph(2'')-Ia* and *ant(6')-Ia* genes were the most common AME genes among HLGR and HLSR enterococci, respectively, and *gelE* was the most frequent virulence determinant.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81460049, No. 81260478), the Natural Science Foundation of Inner Mongolia Autonomous Region of China (No. 2014JQ04, 2015MS0867), the Program for Young Talents of Science and Technology in Universities of the Inner Mongolia Autonomous Region, and the Science Studies

Program in Universities of the Inner Mongolia Autonomous Region, China (NJZY16211).

REFERENCES

- Murray BE. The life and times of the *Enterococcus*. *Clin Microbiol Rev*. 1990;3:46–65.
- Nicoletti G, Stefani S. Enterococci: susceptibility patterns and therapeutic options. *Eur J Clin Microbiol Infect Dis*. 1995;14(suppl 1):S33–S37.
- Mendiratta DK, Kaur H, Deotale V, Thamke DC, Narang R, Narang P. Status of high level aminoglycoside resistant *Enterococcus faecium* and *Enterococcus faecalis* in a rural hospital of central India. *Indian J Med Microbiol*. 2008;26:369–371.
- Agarwal J, Kalyan R, Singh M. High-level aminoglycoside resistance and beta-lactamase production in enterococci at a tertiary care hospital in India. *Jpn J Infect Dis*. 2009;62:158–159.
- Jain S, Kumar A, Kashyap B, Kaur IR. Clinico-epidemiological profile and high-level aminoglycoside resistance in enterococcal septicemia from a tertiary care hospital in east Delhi. *Int J Appl Basic Med Res*. 2011;1:80–83.
- Nepal HP, Khanal B, Acharya A, Gyawali N, Jha PK, Paudel R. High-level gentamicin resistance and vancomycin resistance in clinical isolates of enterococci in a tertiary care hospital in eastern Nepal. *Nepal Med Coll J*. 2012;14:60–63.
- Dada AC, Ahmad A, Usup G, Heng LY, Hamid R. High-level aminoglycoside resistance and virulence characteristics among Enterococci isolated from recreational beaches in Malaysia. *Environ Monit Assess*. 2013;185:7427–7443.
- Jyothi P, Metri B, Peerapur B. High level resistance to aminoglycosides in urinary isolates of enterococci. *Ann Med Health Sci Res*. 2014;4(Special issue 1):S58–S59.
- Padmasini E, Padmaraj R, Ramesh SS. High level aminoglycoside resistance and distribution of aminoglycoside resistant genes among clinical isolates of *Enterococcus* species in Chennai, India. *Sci World J*. 2014;2014:329157.
- French GL. Enterococci and vancomycin resistance. *Clin Infect Dis*. 1998;27(suppl 1):S75–S80.
- Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. *Microbiol Rev*. 1993;57:138–163.
- Wright GD. Aminoglycoside-modifying enzymes. *Curr Opin Microbiol*. 1999;2:499–503.
- Ferretti JJ, Gilmore KS, Courvalin P. Nucleotide sequence analysis of the gene specifying the bifunctional 6'-aminoglycoside acetyltransferase 2-aminoglycoside phosphotransferase enzyme in *Streptococcus faecalis* and identification and cloning of gene regions specifying the two activities. *J Bacteriol*. 1986;167:631–638.
- Chow JW, Zervos MJ, Lerner SA, et al. A novel gentamicin resistance gene in *Enterococcus*. *Antimicrob Agents Chemother*. 1997;41:511–514.
- Tsai SF, Zervos MJ, Clewell DB, Donabedian SM, Sahm DF, Chow JW. A new high-level gentamicin resistance gene: *aph(2)-Id*, in *Enterococcus* spp. *Antimicrob Agents Chemother*. 1998;42:1229–1232.
- Walanj R, Young P, Baker HM, et al. Purification, crystallization and preliminary X-ray analysis of *Enterococcus faecium* aminoglycoside-2-phosphotransferase-Ib [APH(2)-Ib]. *Acta Crystallogr Sect F Struct Biol Cryst Commun*. 2005;61(Pt 4):410–413.
- Kafil HS, Mobarez AM, Moghadam MF. Adhesion and virulence factor properties of Enterococci isolated from

- clinical samples in Iran. *Indian J Pathol Microbiol.* 2013;56:238–242.
18. Medeiros AW, Pereira RI, Oliveira DV, et al. Molecular detection of virulence factors among food and clinical *Enterococcus faecalis* strains in South Brazil. *Braz J Microbiol.* 2014;45:327–332.
 19. Macovei L, Zurek L. Ecology of antibiotic resistance genes: characterization of enterococci from houseflies collected in food settings. *Appl Environ Microbiol.* 2006;72:4028–4035.
 20. Duprè I, Zanetti S, Schito AM, Fadda G, Sechi LA. Incidence of virulence determinants in clinical *Enterococcus faecium* and *Enterococcus faecalis* isolates collected in Sardinia (Italy). *J Med Microbiol.* 2003;52(Pt 6):491–498.
 21. Reviriego C, Eaton T, Martín R, et al. Screening of virulence determinants in *Enterococcus faecium* strains isolated from breast milk. *J Hum Lact.* 2005;21:131–137.
 22. Sepúlveda M, Bello H, Domínguez M, Mella S, Zemelman R, González G. Molecular identification of aminoglycoside-modifying enzymes among strains of *Enterococcus* spp. isolated in hospitals of the VIII Region of Chile. *Rev Med Chil.* 2007;135:566–572.
 23. Emaneini M, Bigverdi R, Kalantar D, et al. Distribution of genes encoding tetracycline resistance and aminoglycoside modifying enzymes in *Staphylococcus aureus* strains isolated from a burn center. *Ann Burns Fire Disasters.* 2013;26: 76–80.
 24. Clinical and Laboratory Standards Institute, Wayne, PA *Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement*; 2014. M100–S23.
 25. Tsiodras S, Gold HS, Coakley EP, Wennersten C, Moellering RC Jr, Eliopoulos GM. Diversity of domain V of 23S rRNA gene sequence in different *Enterococcus* species. *J Clin Microbiol.* 2000;38:3991–3993.
 26. Jia W, Li G, Wang W. Prevalence and antimicrobial resistance of *Enterococcus* species: a hospital-based study in China. *Int J Environ Res Public Health.* 2014;11:3424–3442.
 27. Feizabadi MM, Maleknejad P, Asgharzadeh A, Asadi S, Shokrzadeh L, Sayadi S. Prevalence of aminoglycoside-modifying enzymes genes among isolates of *Enterococcus faecalis* and *Enterococcus faecium* in Iran. *Microb Drug Resist.* 2006;12:265–268.
 28. Vaziri F, Peerayeh SN, Nejad QB, Farhadian A. The prevalence of aminoglycoside-modifying enzyme genes (*aac* (6')-I: *aac* (6')-II, *ant* (2)-I, *aph* (3')-VI) in *Pseudomonas aeruginosa*. *Clinics (Sao Paulo).* 2011;66:1519–1522.
 29. Creti R, Imperi M, Bertuccini L, et al. Survey for virulence determinants among *Enterococcus faecalis* isolated from different sources. *J Med Microbiol.* 2004;53(Pt 1):13–20.
 30. Sharifi Y, Hasani A, Ghotaslou R, et al. Virulence and antimicrobial resistance in enterococci isolated from urinary tract infections. *Adv Pharm Bull.* 2013;3:197–201.
 31. Silva J, Rodríguez Y, Araya J, et al. Detection of virulence genes in aminoglycoside susceptible and resistant *Enterococcus faecalis*. *Rev Chilena Infectol.* 2013;30:17–22.
 32. Eaton TJ, Gasson MJ. Molecular screening of *Enterococcus* virulence determinants and potential for genetic exchange between food and medical isolates. *Appl Environ Microbiol.* 2001;67:1628–1635.